Lupin Soars Over 2% On Getting Nod For Bacterial Infection Medications Lupin Soars Over 2% On Getting Nod For Bacterial Infection Medications Sulfamethoxazole and Trimethoprim Oral Suspension USP is indicated for treating and preventing a variety of bacterial infections, such as middle ear, urine, respiratory, and intestinal infections
Updated: January 07, 2021 10:29 am IST
At 10:25 am, the shares of Lupin were trading at Rs 101.30, up 0.35 per cent on the BSE.
Lupin shares edged higher in early trading after the pharma company, on Wednesday, received approval from the United States Food and Drug Administration (USFDA) for its Sulfamethoxazole and Trimethoprim Oral Suspension USP, 200 mg/40 mg per 5 ml, to market a generic equivalent of Bactrim Oral Suspension, 200 mg/40 mg per 5 mL, of Sun Pharmaceutical Industries, Inc. The shares of Lupin touched an intra-day high of Rs 1,025, up 2.4 per cent in early trading, and at 10:25 am, the shares were trading at Rs 101.30, up 0.35